Zubin J Eapen1, Li Liang2, Jay H Shubrook3, Mary A Bauman4, Vincent J Bufalino5, Deepak L Bhatt6, Eric D Peterson2, Adrian F Hernandez2. 1. Duke Clinical Research Institute, Durham, NC. Electronic address: zubin.eapen@duke.edu. 2. Duke Clinical Research Institute, Durham, NC. 3. Ohio University Heritage College of Osteopathic Medicine, Athens, OH. 4. INTEGRIS Family Care Central, Oklahoma City, OK. 5. Midwest Heart Specialists, Naperville, IL. 6. Veterans Affairs Boston Healthcare System and Brigham and Women's Hospital, Boston, MA.
Abstract
BACKGROUND: Million Hearts is a national initiative to prevent 1 million heart attacks and strokes over 5 years. The degree to which outpatient providers are controlling risk factors has not been fully described. METHODS: We examined adherence to the Million Hearts clinical quality measures using The Guideline Advantage, a nationwide quality improvement program for outpatient care. Specifically, we determined the proportion of patients with (1) ischemic vascular disease who were prescribed an antiplatelet drug; (2) hypertension whose blood pressure was controlled; (3) diabetes mellitus whose most recent low-density lipoprotein cholesterol level was <100 mg/dL; and 4) a tobacco use screening and who received a smoking cessation intervention as needed. RESULTS: From January 1, 2010, to March 31, 2012, there were 147,038 patients enrolled from 25 US practices. At the practice level, antiplatelet prescription ranged from 50.0% to 82.3% (median 71.9%, interquartile range [IQR] 66.7-82.1), hypertension control ranged from 48.6% to 75.3% (median 66.6%, IQR 60.1-70.9), hyperlipidemia control among patients with diabetes mellitus ranged from 53.3% to 100.0% (median 75.8%, IQR 65.8-83.0), and tobacco use screening and intervention ranged from 31.0% to 98.8% (median 79.8%, IQR 72.0-83.2). Black and people of color races were associated with a lower likelihood of blood pressure control and cholesterol control. Female gender was associated with a lower likelihood of antiplatelet prescription and cholesterol control. CONCLUSIONS: Compliance with quality measures for the Million Hearts initiative varies widely and is notable for racial and gender disparities. Our findings identify multiple opportunities to improve the quality of cardiovascular prevention.
BACKGROUND: Million Hearts is a national initiative to prevent 1 million heart attacks and strokes over 5 years. The degree to which outpatient providers are controlling risk factors has not been fully described. METHODS: We examined adherence to the Million Hearts clinical quality measures using The Guideline Advantage, a nationwide quality improvement program for outpatient care. Specifically, we determined the proportion of patients with (1) ischemic vascular disease who were prescribed an antiplatelet drug; (2) hypertension whose blood pressure was controlled; (3) diabetes mellitus whose most recent low-density lipoprotein cholesterol level was <100 mg/dL; and 4) a tobacco use screening and who received a smoking cessation intervention as needed. RESULTS: From January 1, 2010, to March 31, 2012, there were 147,038 patients enrolled from 25 US practices. At the practice level, antiplatelet prescription ranged from 50.0% to 82.3% (median 71.9%, interquartile range [IQR] 66.7-82.1), hypertension control ranged from 48.6% to 75.3% (median 66.6%, IQR 60.1-70.9), hyperlipidemia control among patients with diabetes mellitus ranged from 53.3% to 100.0% (median 75.8%, IQR 65.8-83.0), and tobacco use screening and intervention ranged from 31.0% to 98.8% (median 79.8%, IQR 72.0-83.2). Black and people of color races were associated with a lower likelihood of blood pressure control and cholesterol control. Female gender was associated with a lower likelihood of antiplatelet prescription and cholesterol control. CONCLUSIONS: Compliance with quality measures for the Million Hearts initiative varies widely and is notable for racial and gender disparities. Our findings identify multiple opportunities to improve the quality of cardiovascular prevention.
Authors: Barry L Carter; Barcey Levy; Brian Gryzlak; Yinghui Xu; Elizabeth Chrischilles; Jeffrey Dawson; Mark Vander Weg; Alan Christensen; Paul James; Linnea Polgreen Journal: Circ Cardiovasc Qual Outcomes Date: 2018-06
Authors: Gerald S Bloomfield; Tracy Y Wang; L Ebony Boulware; Robert M Califf; Adrian F Hernandez; Eric J Velazquez; Eric D Peterson; Jennifer S Li Journal: Glob Heart Date: 2015-03
Authors: Michael G Nanna; Ann Marie Navar; Pearl Zakroysky; Qun Xiang; Anne C Goldberg; Jennifer Robinson; Veronique L Roger; Salim S Virani; Peter W F Wilson; Joseph Elassal; L Veronica Lee; Tracy Y Wang; Eric D Peterson Journal: JAMA Cardiol Date: 2018-08-01 Impact factor: 14.676
Authors: Rianneke de Ritter; Marit de Jong; Rimke C Vos; Carla J H van der Kallen; Simone J S Sep; Mark Woodward; Coen D A Stehouwer; Michiel L Bots; Sanne A E Peters Journal: Biol Sex Differ Date: 2020-01-03 Impact factor: 5.027
Authors: Tricia M Peters; Michael V Holmes; J Brent Richards; Tom Palmer; Vincenzo Forgetta; Cecilia M Lindgren; Folkert W Asselbergs; Christopher P Nelson; Nilesh J Samani; Mark I McCarthy; Anubha Mahajan; George Davey Smith; Mark Woodward; Linda M O'Keeffe; Sanne A E Peters Journal: Diabetes Care Date: 2020-12-04 Impact factor: 17.152